BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines

WASHINGTON, D.C. and ROME, Italy, May 13, 2020 – The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.

Sabin Vaccine Institute Strengthens Ebola Sudan and Marburg Vaccines Program with Additional NIAID Partnership

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness and to potentially protect military, first responders, health care and laboratory workers, and other at-risk populations.

This spring and summer, the Sabin Vaccine Institute (Sabin) has been amplifying the voices of parents who immunize through the Give Your Kids A Shot campaign on Twitter

Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services.

Vaccines save millions of lives every year, but recent outbreaks demonstrate the tenuous nature of this achievement. The Sabin Vaccine Institute (Sabin) is launching a research program to better understand the factors leading some to accept vaccination and others to delay or refuse it.

GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute

LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.

When Ebola virus disease swept through Guinea, Liberia and Sierra Leone in 2014, the world saw firsthand the shortcomings of the global response.

Global Communities had spent four years building access to safe sanitation in Liberia when the Ebola epidemic struck and revealed a surprising impact.

Pages